Esophageal Cancer in North America
Death rates for Esophageal Cancer across 3 countries in North America.
| # | Country | Rate |
|---|
Esophageal cancer kills approximately 544,000 people annually, making it one of the most lethal cancers globally with a five-year survival rate below 20%. Two main histological subtypes exist: squamous cell carcinoma (SCC), predominant in East Asia, sub-Saharan Africa, and parts of South America; and adenocarcinoma, increasingly common in North America, Europe, and Australasia. SCC risk factors include tobacco, alcohol, hot beverage consumption, poor nutritional status, and nitrosamine exposure. Adenocarcinoma is driven by gastro-oesophageal reflux disease (GORD) and Barrett's oesophagus, with obesity as a major contributing factor. The 'Asian oesophageal cancer belt' — stretching from Turkey through Central Asia to China — has extraordinarily high SCC rates, likely related to dietary and environmental exposures. Oesophageal cancer typically presents with dysphagia at an advanced stage, and late diagnosis remains the primary driver of poor outcomes globally. North America has among the world's highest health expenditure per capita, yet faces distinctive mortality challenges including the opioid epidemic, firearm violence, rising metabolic disease, and significant health disparities linked to race and income. In North America, esophageal cancer mortality is near global averages — a pattern shaped by the tension between world-leading medical capabilities and persistent disparities in healthcare access and social determinants of health.
Tobacco and alcohol cessation substantially reduce SCC risk. Weight management and treatment of GORD address adenocarcinoma risk factors. Endoscopic screening in high-incidence regions (particularly China) enables early detection of dysplasia and superficial cancers amenable to endoscopic resection. Dietary improvements — increased fruit and vegetable intake, reduced consumption of very hot beverages and pickled/cured foods — are population-level strategies. Barrett's oesophagus surveillance detects progression to adenocarcinoma.
The mortality estimates presented on this page are derived from the Global Burden of Disease (GBD) study, produced by the Institute for Health Metrics and Evaluation (IHME). The GBD synthesizes data from vital registration systems, verbal autopsies, cancer registries, and surveillance networks across more than 200 countries and territories. Death rates are expressed per 100,000 population and are age-standardized, which adjusts for differences in age structure between populations so that comparisons across countries and over time reflect genuine differences in mortality risk rather than demographic composition.
The dataset typically covers the period from 1990 to 2023, although availability varies by country and cause. When interpreting the figures for esophageal cancer in North America, note that higher age-standardized rates indicate a greater mortality burden independent of whether a country's population is older or younger. Trends over time reveal whether public health interventions, economic development, and health system improvements have reduced or increased the toll of this condition in the region.
Cancer mortality data combine information from population-based cancer registries, vital registration systems, and statistical modeling where direct data are sparse. Incidence-to-mortality ratios and survival estimates help distinguish regions where high death rates stem from high incidence versus those where limited access to early detection and treatment drives poor outcomes. For esophageal cancer across North America, comparing mortality rates alongside screening coverage and treatment availability provides crucial context for understanding regional disparities.